Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Not pending/lapsed |
21 | DE file number | DAKZ | 603 37 552.9 |
96 | EP file number | EAKZ | 03 72 6489.2 |
86 | WO file number | WAKZ | PCT/US03/13063 |
97 | EP publication number | EPN | 1503788 |
87 | WO publication number | WPN | 2003090695 |
54 | Designation/title | TI | BEHANDLUNG DES ALPHA-GALACTOSIDASE A MANGELS |
51 | IPC main class | ICM (ICMV) | A61K 38/43 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | A61K 38/47 (2006.01) |
22 | DE application date | DAT | Apr 25, 2003 |
96 | EP application date | EAT | Apr 25, 2003 |
86 | WO application date | WAT | Apr 25, 2003 |
43 | Date of first publication | OT | Nov 6, 2003 |
| Date of publication of grant | PET | Jun 29, 2011 |
71/73 | Applicant/owner | INH | Takeda Pharmaceutical Company Limited, Osaka-shi, Osaka, JP |
72 | Inventor | IN | BOROWSKI, Marianne, Glen, NH 03838-3156, US; TRECO, Douglas, A., Arlington, MA 02476, US |
| Address for service | | Takeda Pharmaceutical Company Ltd., OSAKA-SHI, OSAKA 541-0045, JP |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 375584 P Apr 25, 2002
|
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
87 | WO language of publication | WLANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR |
81 | Designated WO countries | WDS | LT, AL, LV, MK |
| Published EP/WO documents | EPWOPN | Original document: EP000001503788 Searchable text:
EP000001503788 Original document:
EP000001503788B1 Searchable text:
EP000001503788B1 Original document:
WO002003090695 Searchable text:
WO002003090695 |
43 | Date of first publication | EVT | Nov 6, 2003 |
| Date of the first transfer into DPMAregister | EREGT | May 27, 2011 |
| Date of the (most recent) update in DPMAregister | REGT | Apr 27, 2023 (Show all update days)(Hide all update days)- May 27, 2011
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 6)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Jun 24, 2011 |
| Issue number | HN | 38 |
| Year | PJ | 2021 |
| Publication date | VT | Sep 23, 2021 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Shire Human Genetic Therapies, Inc., Cambridge, Mass., US |
71/73 | Previous applicant/owner | INHF | Transkaryotic Therapies, Inc., Cambridge, Mass., US |
| Date of update of the procedure | REGT | Sep 23, 2021 |
View procedures New applicant/owner details (No.: 12)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Aug 13, 2021 |
| Issue number | HN | 38 |
| Year | PJ | 2021 |
| Publication date | VT | Sep 23, 2021 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Takeda Pharmaceutical Company Limited, Osaka-shi, Osaka, JP |
71/73 | Previous applicant/owner | INHF | Shire Human Genetic Therapies, Inc., Cambridge, Mass., US |
| Date of update of the procedure | REGT | Sep 23, 2021 |